It's Fluid! Not Fat. Obesity Explained.

This paper proposes that a substantial subset of patients diagnosed with treatment-resistant obesity actually have inflammatory lymphedema driven by the rs5522 genetic variant, which causes mineralocorticoid receptor (MR) hyperactivity. The rs5522 variant (affecting 12-20% of populations depending on ancestry) leads to chronic vascular leak, interstitial fluid accumulation, macrophage infiltration, cytokine production (IL-23, IL-6), and eventual fibrotic walling of inflammatory fluid which creates mass that appears as “obesity” but is actually trapped fluid in scar tissue cages.

 

Standard weight loss interventions fail because they target caloric excess when the actual mechanism is hydraulic failure. Evidence suggests that what obesity research measures as “fat loss” may primarily be fluid mobilization, explaining the 1-2 lb/week “safe rate” (electrolyte safety during fluid shifts, not metabolic constraints), the rebound phenomenon (fluid re-accumulation when MR hyperactivity unaddressed), and observations from The Biggest Loser (weight loss too rapid for pure fat oxidation, complete regain except in those maintaining extreme exercise-induced fluid mobilization state).

 

The paper also addresses systemic barriers to paradigm shift: pharmaceutical business models favoring expensive downstream biologics ($60,000/year IL-23 inhibitors) over upstream generic fixes; medical education gaps (10-20 year lag from research to practice); gender role enforcement in medical symptom interpretation harming both sexes; and the need to remove corporate money from medical education, guideline development, and politics.

Includes treatment protocols, cost analyses, research priorities, and calls for clinical trials of spironolactone in rs5522-positive treatment-resistant obesity patients.